What does BARDA do for global health R&D?

The Biomedical Advanced Research and Development Authority (BARDA) supports the development of vaccines, drugs, and other medical countermeasures (MCMs) to protect Americans against threats to public health, including emerging infectious diseases, pandemic influenza, and antimicrobial resistance (AMR).

Why is BARDA’s role in global health R&D important?

BARDA works with industry and other partners to bridge the “valley of death” between basic research and product development, where research and development (R&D) efforts most often fail. Through unique contracting and incentive mechanisms, BARDA’s partnerships ensure promising research is translated into urgently needed medical products by creating commercial incentives for developers that would otherwise not exist. During the COVID-19 pandemic, BARDA’s prominence and funding has grown exponentially as the agency was charged with leading the US government’s MCM R&D portfolio, demonstrating how—with sufficient, sustained funding—BARDA is uniquely equipped to advance products against a range of other global health threats.

Impact of investment

<table>
<thead>
<tr>
<th>BARDA support has helped advance:</th>
<th>8</th>
<th>FDA-approved products for Ebola &amp; Zika</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>75+</td>
<td>products in development for COVID-19</td>
</tr>
<tr>
<td></td>
<td>78</td>
<td>projects to advance innovations for AMR</td>
</tr>
</tbody>
</table>

BARDA R&D success stories: Saving lives, saving money

**COVID-19**

Led US COVID-19 product development efforts for vaccines, diagnostics, and therapeutics, supporting dozens of innovations, including all vaccines approved by the US Food and Drug Administration (FDA).

**EBOLA**

Development of the world’s first Ebola vaccine, as well as two Ebola treatments and one rapid diagnostic test approved by the FDA.

**AMR**

Accelerating antibacterial research through the CARB-X public-private partnership, which has supported 78 projects in ten countries, to build the world’s largest early development pipeline of antibacterial innovations.

**ZIKA**

Development of six FDA-approved diagnostics, including tests to identify infection and screen blood supplies, and several Zika vaccine candidates in development.

**INFLUENZA**

Strengthening manufacturing capacity in low- and middle-income countries to enable rapid production of seasonal and pandemic influenza vaccines.

www.ghtcoalition.org